| Applications: |
WB |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
PCSK9 Positive Control for STJ501875 is synthetically produced from the sequence and is suitable for use in western blot applications. |
| Formulation: |
Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is |
| Dilution Range: |
WB: 1:500 |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
Pcsk9 |
| Gene ID: |
100102 |
| Uniprot ID: |
PCSK9_MOUSE |
| Specificity: |
This is positive control is recommended for use in combination with PCSK9 antibody STJ501875. |
| Tissue Specificity | Hepatocytes, kidney mesenchymal cells, intestinal ileum, colon epithelia and embryonic brain telencephalon neurons. |
| Post Translational Modifications | Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation. Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein. Phosphorylation protects the propeptide against proteolysis. |
| Function | Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. |
| Peptide Name | Proprotein Convertase Subtilisin/Kexin Type 9Neural Apoptosis-Regulated Convertase 1Narc-1Proprotein Convertase 9Pc9Subtilisin/Kexin-Like Protease Pc9 |
| Database Links | Reactome: R-MMU-381426Reactome: -MMU-8866427Reactome: -MMU-8957275Reactome: -MMU-8964038 |
| Cellular Localisation | CytoplasmSecretedEndosomeLysosomeCell SurfaceEndoplasmic ReticulumGolgi ApparatusAutocatalytic Cleavage Is Required To Transport It From The Endoplasmic Reticulum To The Golgi Apparatus And For The Secretion Of The Mature ProteinLocalizes To The Endoplasmic Reticulum In The Absence Of Ldlr And Co-Localizes To The Cell Surface And To The Endosomes/Lysosomes In The Presence Of LdlrThe Sorting To The Cell Surface And Endosomes Is Required In Order To Fully Promote Ldlr Degradation |
| Alternative Peptide Names | Proprotein Convertase Subtilisin/Kexin Type 9 proteinNeural Apoptosis-Regulated Convertase 1 proteinNarc-1 proteinProprotein Convertase 9 proteinPc9 proteinSubtilisin/Kexin-Like Protease Pc9 proteinPcsk9 proteinNarc1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
